Nesiritide of no benefit in acute CHF

Nesiritide in recombinant BNP (that promotes vasodilation) which was FDA approved for use in acute decompensated CHF. However, a large randomized trial, there were no differences in several outcomes in nesiritide compared to placebo (including patient dyspnea scores, 30 day mortality, or 30 day readmission rates), but nesiritide patients were more likely to experience hypotension. Nesiritide cannot be recommended for use in acute CHF (abstract)